Pityriasis rosea in a hepatitis b-positive patient treated with pegylated interferon α2a: Report of a case and review of the literature

Francesco Drago, Sanja Javor, Linda Bruzzone, Francesca Drago, Aurora Parodi, Antonino Picciotto

Research output: Contribution to journalArticle


Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease caused by the endogenous reactivation of human herpesvirus (HHV)-6 and/or HHV-7 infection in conditions of altered immunity. In addition, many drugs have been incriminated as possible triggers of PR-like eruptions, characterized by clinical, morphological and histopathological features that differ from typical PR. Here, we report a case of PR in a patient with chronic hepatitis B, receiving pegylated interferon α2a (PEG-IFN- α2a). PR, arising after the second administration of the PEG-IFN-α2a, might be considered a clinical expression of the patient's altered immune condition as reported in the immune reconstitution inflammatory syndrome affecting patients with human immunodeficiency virus infection after high-dose antiretroviral therapy.

Original languageEnglish
Pages (from-to)10-13
Number of pages4
Issue number1
Publication statusPublished - Feb 2014



  • Chronic hepatitis B
  • Immune reconstitution inflammatory syndrome
  • Pegylated interferon α
  • Pityriasis rosea

ASJC Scopus subject areas

  • Dermatology

Cite this